<DOC>
	<DOCNO>NCT01526096</DOCNO>
	<brief_summary>The purpose study test whether regulatory T-cell reduction possible safe myeloma subject undergo autologous stem cell transplantation ( ASCT ) .</brief_summary>
	<brief_title>Stem Cell Transplantation Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Symptomatic multiple myeloma subtype disease stage , provide patient smolder myeloma . Patient must otherwise candidate ASCT determine treat physician . No current CNS Myeloma time enrollment . Life expectancy great 12 week . Age great equal 21 less equal 70 year old . EGOG performance status less equal 2 . No cardiac , pulmonary , hepatic , renal contraindication high dose chemotherapy . HIV Negative . No active Hepatitis B C. Patients must able provide write informed , consent . Pregnant nursing woman . Women childbearing age must test pregnancy . Use systemic immunosuppressive medication , include corticosteroid , tacrolimus , mycophenolate mofetil , sirolimus cyclosporine A . Psychiatric illness may make compliance clinical protocol unmanageable may compromise ability patient give inform consent . Active autoimmune disease include limited : rheumatoid arthritis inflammatory bowel disease , celiac disease , systemic lupus erythematosis , scleroderma multiple sclerosis .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>